Accomplished in the development and execution of innovative Canadian regulatory strategies, Chris brings to FORUS over 20 years of Regulatory focused industry and operational leadership. With experience gained from Celgene and GlaxoSmithKline in product development and regulatory affairs, he has led numerous Canadian regulatory filings bringing forth innovative treatments to patients with serious and rare diseases. In addition to his Regulatory focus, Chris oversees FORUS’s Pharmacovigilance and Quality Assurance functions, ensuring our pioneering medicines are of the highest quality and meet the safety standards needed for Canadian patients. Chris holds an Honours Bachelor of Science degree in Pharmacology and Toxicology from the University of Western Ontario.